NCT03993704 is a Phase 1 clinical trial of LHF-535 in Healthy, sponsored by Kineta Inc..

Who is sponsoring NCT03993704?

NCT03993704 is sponsored by Kineta Inc..

What drugs are being tested in NCT03993704?

Interventions in NCT03993704: LHF-535.

Is NCT03993704 still recruiting?

NCT03993704 is currently completed. Last updated 9 July 2020.

Last reviewed 2020-07-09 · How we verify

NCT03993704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

Completed Phase 1 Last updated 9 July 2020

What this trial tests

Phase 1 trial testing LHF-535 in Healthy in 24 participants. Completed in 9 June 2020.

Timeline

16 September 2019

Primary endpoint
9 January 2020

9 June 2020

Quick facts

Lead sponsor	Kineta Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	24
Start date	16 September 2019
Primary completion	9 January 2020
Estimated completion	9 June 2020
Sites	1 location across Australia

Drugs / interventions tested

LHF-535 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Kineta Inc. — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a daily oral dose of LHF-535 administered for 14 days to healthy participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment of highly virulent mammarenavirus infections-status quo and future directions.
Nuñez IA, Crane A, Crozier I, Worwa G, et al · · 2024 · cited 2× · PMID 38606475 · DOI 10.1080/17460441.2024.2340494

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Kineta Inc. trials

Trials by the same sponsor.

NCT05708950 — A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03993704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kineta Inc.
Last refreshed: 9 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03993704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing